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Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer and has a high rate of mor-
tality. Emerging evidence indicates that hepatocyte growth factor receptor (or Met) pathway plays a pivotal role in
HNSCC metastasis and resistance to chemotherapy. Met function is dependent on tyrosine phosphorylation that is
under direct control by receptor-type protein tyrosine phosphatase β (RPTP-β). We report here that RPTP-β expres-
sion is significantly downregulated in HNSCC cells derived from metastatic tumors compared to subject-matched
cells from primary tumors. Knockdown of endogenous RPTP-β in HNSCC cells from primary tumor potentiated Met
tyrosine phosphorylation, downstream mitogen-activated protein (MAP) kinase pathway activation, cell migration,
and invasion. Conversely, restoration of RPTP-β expression in cells from matched metastatic tumor decreased Met
tyrosine phosphorylation and downstream functions. Furthermore, we observed that six of eight HNSCC tumors
had reduced levels of RPTP-β protein in comparison with normal oral tissues. Collectively, the results demonstrate
the importance of RPTP-β in tumor biology of HNSCC through direct dephosphorylation of Met and regulation of
downstream signal transduction pathways. Reduced RPTP-β levels, with or without Met overexpression, could
promote Met activation in HNSCC tumors.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most
common cancer worldwide, accounting for 6% of all cancers [1,2].
Despite advances in aggressive multidisciplinary treatments, the 5-year
survival rate for HNSCC is lower than that for other cancers such as
lymphoma, breast cancer, and malignant melanoma. The high mortal-
ity rate of HNSCC is due to frequent recurrence and early involvement
of regional lymph nodes and subsequent metastasis [3,4]. HNSCC
metastasis is a multistage process including cellular detachment, proteo-
lytic degradation of the basement membrane, migration through extra-
cellular matrix, and resistance to apoptosis in a new environment [5].
Met, also known as hepatocyte growth factor (HGF) receptor, is
a member of the receptor protein tyrosine kinase (PTK) family. The
Met signaling pathway has been shown to promote various stages of
HNSCC metastasis [6–12]. Expression of Met and/or its ligand HGF
increases during HNSCC progression [13–18]. Met expression is
significantly increased in affected lymph nodes compared to corre-
sponding primary tumors [15,18]. In addition, activating mutations
of Met are specifically selected during HNSCC metastasis [19]. In-
creased expression of HGF has also been positively linked to lymph
node metastasis of HNSCC [14,20–23]. Inappropriate completion
of HGF/Met autocrine loop increases tumorigenesis and enhances
metastatic activity [24]. Accordingly, Met expression often correlates
with poor prognosis [25,26]. Consistent with the in vivo data, HGF
stimulation of Met-expressing HNSCC cell lines promotes an invasive
phenotype [7,27]. Collectively, compelling evidence exists that the
HGF/Met axis is an important driving force in HNSCC metastasis.
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Receptor-type protein tyrosine phosphatase β (RPTP-β) belongs to
the family of RPTPs which have been implicated in cell-cell and cell-
matrix interactions [28,29]. RPTP-β, encoded by the ptprb gene, is
composed of an extracellular domain with cell adhesion molecule–
like motif (multiple fibronectin type 3–like domains), a transmembrane
domain, and a single intracellular protein tyrosine phosphatase domain
[30,31]. RPTP-β is localized to chromosome 12 of human genome
where abnormalities occur in some benign tumors whose cells have lost
contact inhibition [32]. We have recently demonstrated that RPTP-β
directly binds to and specifically dephosphorylates Met in vitro and in
intact primary human keratinocytes [33].
We report here that RPTP-β is significantly reduced in cells derived
from HNSCC metastatic tumors. Restoration of RPTP-β expression
normalizes Met tyrosine phosphorylation, downstream signaling, pro-
liferation, migration, and invasion. In addition, immunohistology
reveals that RPTP-β is commonly reduced in HNSCC. These data
indicate that down-regulation of RPTP-β may be a prominent mech-
anism of aberrant Met regulation in HNSCC.
Materials and Methods
Materials
Recombinant human HGF was purchased from R&D Systems
(Minneapolis, MN). Met, extracellular-signal-regulated kinase (ERK),
and RPTP-β antibodies and protein A/G agarose were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Phospho-Met
(pY1349/1356) antibody was purchased from Rockland (Gilbertsville,
PA). Phospho-Met (pY1356) antibody was purchased from Abgent
(San Diego, CA). Mitogen extracellular kinase (MEK), phospho-ERK
and phospho-MEK antibodies were purchased from Cell Signal-
ing Technology (Beverly, MA). Grb2 antibody was purchased from
BD Biosciences (San Jose, CA).
Cell Culture
HNSCC cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS under 5%CO2 at 37°C. The identities of
all HNSCC cell lines used in the experiments have been confirmed by
DNA genotyping using 10 short tandem repeats (STRs) in the Profiler
Plus (Applied Biosystems, Foster City, CA) for human identification.
UMSCC-17A and UMSCC-17B were established from a patient with
squamous cell cancer of the larynx. UMSCC-17A was from the tumor
within the larynx, and UMSCC-17B was from metastasis through the
cartilage into the soft tissues of the neck [34]. UMSCC-22A was from a
patient with squamous cell cancer of the hypopharynx, and UMSCC-
22B was from a metastasis to a lymph node in the neck [35].
Preparation of Whole-Cell Lysates and Immunoprecipitation
After treatment, HNSCC cells were washed twice with ice-cold
phosphate-buffered saline, scraped from the culture plates in ice-cold
whole-cell extraction buffer [25 mM Hepes (pH 7.2), 75 mM NaCl,
2.5 mMMgCl2, 0.2 mM EDTA, 20mM β-glycerophosphate, 0.5 mM
DTT, and 0.1% Triton X-100], and supplemented with protease
inhibitor cocktail (Cat. No. 11697498001; Roche Diagnostics,
Indianapolis, IN) and 1 mM sodium orthovanadate (Sigma-Aldrich,
St Louis, MO). Following 10 minutes of incubation at 4°C, whole-cell
homogenate was centrifuged at 14,000g for 10 minutes. The resultant
supernatant represented whole-cell lysate. For immunoprecipitation,
whole-cell lysates were pre-cleared with protein A/G agarose and incu-
bated with primary antibody overnight at 4°C, followed by incubation
with protein A/G agarose for 2 hours at 4°C. After extensive washing
with immunoprecipitation buffer [20 mM Hepes (pH 7.2), 100 mM
NaCl, 10% glycerol, and 0.1% Triton X-100], agarose-bound proteins
were subjected to sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis and analyzed by Western blot.
Western Blot Analysis
Equal amounts of protein (same concentration and volume) from
whole-cell lysates were resolved by a 10% sodium dodecyl sulfate–
polyacrylamide gel (Invitrogen, Carlsbad, CA) and transferred to
Immobilon-P filter paper (Millipore, Bedford, MA). Immunoreactive
proteins were visualized by enhanced chemifluorescence as per the
manufacturers’ instructions (GE Healthcare, Buckinghamshire, United
Kingdom). Quantification of chemifluorescence was performed using a
STORM PhosphorImager device (GE Healthcare) with ImageQuant
software (Molecular Dynamics, Sunnyvale, CA). Sample loads, anti-
body concentration, and incubation times were adjusted to yield fluo-
rescent signals within the linear range of detection.
Adeno-X Expression Vector Construction and
Adenovirus Production
Wild-type human RPTP-β cDNA was cloned into pShuttle expres-
sion vectors, and RPTP-β expression cassette was subsequently ligated
with linearized Adeno-X Viral DNA using the Adeno-X Expression
System according to the manufacturer’s protocol (Clontech Labora-
tories, Inc, Palo Alto, CA). Human embryonic kidney 293 (HEK293)
cells were used for adenovirus production and purification.
Lentivirus-mediated shRNA Silencing of RPTP-β
in HNSCC Cells
MISSIONTurboGFP shRNA non-targeting (NT) control vector and
shRNA constructs targeting RPTP-β (5′-CCGGCGGGTGTATCA-
GACTAATTATCTCGAGATAATTAGTCTGATACACCCGTT-
TTT-3′) were purchased from Sigma-Aldrich. Lentivirus particles were
generated after transient transfection of RPTP-β shRNA construct DNA
and helper plasmids into 293FT cells using the Superfection method ac-
cording to the manufacturers’ instructions (Qiagen, Hilden, Germany).
Two days after transfection, cell culture medium was collected and used
to infect human HNSCC cells to knockdown endogenous RPTP-β.
Quantitative Real-time Reverse Transcription–Polymerase
Chain Reaction
Total cellular RNA was extracted from HNSCC cells using the Mini-
prep RNA isolation kit as per the manufacturers’ instructions (Qiagen).
Total cellular RNA (100 ng) was reverse transcribed with random prim-
ers using TaqMan Reverse Transcription Kit (Applied Biosystems).
Quantitative real-time polymerase chain reaction (PCR) was performed
using a TaqMan GEx PCR Master Mix Kit (Applied Biosystems) and a
7300 Sequence Detector (Applied Biosystems). RPTP-β and house-
keeping gene 36B4 mRNA levels were quantified and normalized to
36B4. Primers for real-time PCR were given as follows: RPTP-β sense
primer, 5′-GGACCATCCGGGAGTTTAAGA-3′; RPTP-β antisense
primer, 5′-AAGTGGCGGATGAGTCTGTGT-3′; 36B4 sense primer,
5′-ATGCAGCAGATCCGCATGT-3′; and 36B4 antisense primer,
5′-TTGCGCATCATGGTGTTCTT-3′.
Cell Migration Assay
Mitomycin (10 μg/ml)–treated confluent monolayers of HNSCC
cells were scratched with a pipette tip to create a cell-free zone and
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incubated with or without 10 ng/ml HGF. Cells that migrated into
the cell-free zones were photographed after staining with Cell Stain
Solution (Cell Biolabs, San Diego, CA).
Matrigel Invasion Assay
Matrigel invasion assays were carried out according to the manu-
facturer’s instructions (Cell Biolabs). Briefly, HNSCC cells were cul-
tured in matrigel invasion assay wells with or without 10 ng/ml HGF.
Cells that passed through the matrigel were stained with Cell Stain
Solution (Cell Biolabs) and photographed.
Immunohistochemistry
HNSCC tumor tissue sections were purchased from US Biomax
(Rockville, MD). After melting the wax at 65°C, tissue sections were
deparaffinized in xylene three times, 3 minutes each. The sections were
rehydrated through a series of methanol/water solutions three times,
3 minutes each. Antigen retrieval was performed by incubating the
sections in antigen-retrieval buffer (6.5 mM sodium citrate, pH 6.0) at
60°C overnight. Endogenous peroxidase was quenched by immersing the
sections in Peroxide Block (Biogenex, Fremont, CA) for 10 minutes, fol-
lowed by incubation with Protein Block for 20 minutes to minimize
nonspecific background staining. Sections were then incubated with
10 μg/ml Met C-12, RPTP-β H300 primary antibodies, or control
IgG from Santa Cruz Biotechnology at room temperature for 1 hour.
Sections were subsequently incubated with Multi-Link anti-(R+M)
(Biogenex) for 10 minutes, followed by streptavidin HRP (Biogenex) for
10 minutes. Color was developed by incubating with AEC (Biogenex)
for 3 minutes for detection. Sections were thoroughly washed, counter-
stained with hematoxylin, mounted, and photographed.
Results
RPTP-β Is Downregulated in Human Metastatic
Tumor HNSCC Cells
We initially quantified RPTP-β transcript levels inHNSCC cell lines
established from eight individuals [34,36]. Cells derived from both pri-
mary and matched metastatic tumors were available from two individ-
uals. RPTP-β mRNA levels in HNSCC cells derived from primary
tumors were similar to normal human oral keratinocytes (HOKCs; data
not shown). Importantly, RPTP-β mRNA and protein expression was
nearly undetectable in both cell lines derived from metastatic tumors
(UMSCC-17B and UMSCC-22B) (Figure 1).
RPTP-β Regulates Met Tyrosine Phosphorylation
in HNSCC Cells
Loss of RPTP-β could drive Met activation. Therefore, we investi-
gated the role of RPTP-β in regulating Met functions in HNSCC cell
lines derived from both the primary and the metastatic tumors of the
same individual (UMSCC-22A and UMSCC-22B, respectively). We
either restored RPTP-β expression in metastatic tumor UMSCC-22B
cells that lack endogenous RPTP-β protein or knocked down endoge-
nous RPTP-β expression in UMSCC-22A primary tumor cells. We then
determined the ability of RPTP-β to counteract both basal and HGF-
induced Met tyrosine phosphorylation in these two HNSCC cell lines.
Restored expression of RPTP-β in metastatic tumor UMSCC-22B
cells significantly reduced both basal and HGF-stimulatedMet tyrosine
Figure 1. RPTP-β is downregulated in metastatic HNSCC cell lines.
Total RNA and whole-cell lysates were prepared from HOKCs, cells
fromprimary HNSCC tumors (UMSCC-17A andUMSCC-22A), and cells
from metastatic HNSCC tumors of the same patients (UMSCC-17B
and UMSCC-22B). RPTP-βmRNA and internal control housekeeping
gene 36B4 were quantified by real-time reverse transcription–PCR.
RPTP-β mRNA was not detectable in cells from secondary meta-
static tumors. Inset shows representative Western blot of RPTP-β
protein, with β-actin used as loading control. N = 3–6, *P < .05
versus HOKCs.
Figure 2. RPTP-β regulates Met tyrosine 1356 phosphorylation in
HNSCC cells. (A) UMSCC-22B metastatic HNSCC tumor cells were
infected with empty adenovirus or RPTP-β–expressing adenovirus.
(B) UMSCC-22A primary HNSCC tumor cells were infected with
NT or RPTP-β–targeting shRNA lentivirus. Forty-eight hours post-
infection, cellswere treatedwith vehicle (−) or HGF (10 ng/ml,+) for
30 minutes. Equal amounts of whole-cell lysates were analyzed by
Western blot probed with indicated antibodies. Immunoreactive
bandswere quantified by chemifluorescence using a STORM Image
analyzer. Data are means ± SEM, N = 3; *P < .05. Inset shows
representative Western blots.
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1356 phosphorylation. Basal tyrosine phosphorylation was reduced
by 20% and HGF-stimulated phosphorylation was reduced by 70%
(Figure 2A). In primary tumor UMSCC 22A cells, lentivirus shRNA-
mediated knockdown reduced RPTP-β by 70%. This reduction
increased both basal and HGF-stimulated Met tyrosine 1356 phos-
phorylation by two-fold (Figure 2B). Similar results were obtained with
other cells, including primary normal human keratinocytes, UMSCC-9
and UMSCC-17B, and another shRNA construct targeting a different
region of RPTP-β yielded similar results (data not shown). These data
indicate that down-regulation of RPTP-β is functionally similar to
activation of Met by HGF. Furthermore, it is notable that altered
Met activity in response to reduced RPTP-β expression occurs without
change in total Met expression. These data illustrate the importance of
the Met/RPTP-β ratio in determining Met activation.
Figure 3. RPTP-β regulates HGF-induced Grb2 binding to Met and downstream activation of MEK and ERK in HNSCC cells. (A) UMSCC-
22B metastatic HNSCC tumor cells were infected with empty adenovirus or RPTP-β–expressing adenovirus. Forty-eight hours post-
infection, cells were treated with vehicle (−, Ctrl) or HGF (10 ng/ml, +) for 15 minutes. Met was immunoprecipitated from whole-cell
lysates, and immunoprecipitates were analyzed for Grb2 and Met by Western blot. (B and C) UMSCC-22B cells were treated as in A,
except HGF treatment time was 30 minutes, and analyzed for MEK phosphorylation (B) and ERK phosphorylation (C). (D and E) UMSCC-
22A primary HNSCC tumor cells were infected with NT or RPTP-β–targeting shRNA lentivirus. UMSCC-22A cells were treated as in A,
except HGF treatment time was 30 minutes, and analyzed for MEK phosphorylation (D) and ERK phosphorylation (E). Immunoreactive
bands were quantified by chemifluorescence using a STORM Image Analyzer. Data are means ± SEM, N = 3; *P < .05. Insets show
representative Western blots.
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RPTP-β Regulates HGF-induced MEK and ERK Activation
in HNSCC Cells
Met tyrosine 1356 phosphorylation serves as a docking site for Grb2
binding [37,38] that leads to activation of Ras/MAP kinase pathway.
Because RPTP-β regulates tyrosine 1356 phosphorylation in UMSCC-
22A and UMSCC-22B cells, we examined the effect of RPTP-β expres-
sion on basal and HGF-stimulated binding of Grb2 to Met. Expression
of RPTP-β in metastatic tumor UMSCC-22B cells reduced HGF-
stimulated Grb2 binding to Met by 70% (Figure 3A). Consistent with
these data, expression of RPTP-β in metastatic tumor UMSCC-22B
cells inhibited both basal and HGF-induced MEK1/2 activation by
40% and 70%, respectively (Figure 3B). Expression of RPTP-β inhib-
ited basal p44 and p42 forms of ERK by 55% and 40%, respectively,
and almost completely suppressed HGF-induced activation of both
p44 and p42 ERK (Figure 3C ). In primary tumor UMSCC-22A cells,
knockdown of endogenous RPTP-β increased basal level of MEK1/2
to that of HGF stimulation and further potentiated HGF-induced
MEK1/2 activation by 50% (Figure 3D). Knockdown of endogenous
RPTP-β also increased basal p44 and p42 ERK to the level of HGF-
stimulated activation and further potentiated HGF-induced p44 and
p42 ERK activation by 30% and 40%, respectively (Figure 3E).
RPTP-β Regulates Met-mediated Migration, Proliferation,
and Invasion of HNSCC Cells
MAP kinase activation by HGF has been shown to promote cell
migration and proliferation in wound healing and tumor metastasis
[39–41]. Therefore, we examined the impact of RPTP-β expression
on migration and proliferation of primary tumor UMSCC-22A and
metastatic tumor UMSCC-22B cells. Restored expression of RPTP-β,
which inhibits HGF-induced MEK/ERK activation (Figure 3, A and
B), abolished HGF-induced migration of UMSCC-22B, as measured
by a scratch assay in the presence of proliferation inhibitor mitomycin
(Figure 4A). Conversely, knockdown of endogenous RPTP-β in
UMSCC-22A cells substantially potentiated both basal and HGF-
stimulated UMSCC-22A cell migration (Figure 4B).
In addition to migration, we determined the effect of RPTP-β resto-
ration on proliferation of metastatic tumor UMSCC-22B cells. Cells
were plated at low density and infected with either empty or RPTP-β
adenovirus. Cells infected with control adenovirus went through two
population doublings between days 1 and 2 post-infection and more
than two population doublings between days 2 and 3 post-infection.
In stark contrast, cells infected with RPTP-β adenovirus failed to dou-
ble after 3 days (Figure 5). This inhibition of proliferation by restora-
tion of RPTP-β was similar to inhibition by a specific Met kinase
inhibitor [42] (data not shown).
We next examined the role of RPTP-β in HNSCC cell invasion, us-
ing matrigel cell invasion assays. Metastatic tumor–derived UMSCC-
17B and UMSCC-22B cells that do not express RPTP-β are highly
invasive compared to primary tumor–derived UMSCC-17A and
UMSCC-22A cells, which express RPTP-β (data not shown). Thus,
loss of RPTP-β, which results in increased Met function, may be a
mechanism for elevated metastatic potential in HNSCC. To test this
Figure 4. RPTP-β regulates HGF-induced HNSCC cell migration. (A) UMSCC-22B metastatic HNSCC tumor cells were infected with
empty adenovirus or RPTP-β–expressing adenovirus. (B) UMSCC-22A primary HNSCC tumor cells were infected with NT or RPTP-β–
targeting shRNA lentivirus. Forty-eight hours post-infection, confluent cells were treated with 10 μg/ml mitomycin for 30 minutes and
scratched with a pipette tip to create a cell-free zone. Cells were then incubated with or without HGF (10 ng/ml) for 48 hours. A repre-
sentative image of three independent experiments is shown.
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possibility, we restored RPTP-β expression in metastatic tumor
UMSCC-22B cells and reduced RPTP-β expression in primary tumor
UMSCC-22A cells. As shown in Figure 6A, restoration of RPTP-β ex-
pression completely inhibited both basal and HGF-stimulated invasion
of UMSCC-22B. Conversely, knockdown of endogenous RPTP-β in
UMSCC-22A cells increased both basal and HGF-stimulated invasion
(Figure 6B).
RPTP-β Is Commonly Downregulated in HNSCC Tumors
Collectively, the above data demonstrate the importance of RPTP-β
in regulation of Met phosphorylation and key downstream cellular
responses in HNSCC cells. As proof of concept, we assessed the rela-
tive protein levels of Met and RPTP-β in a small number of invasive
HNSCC tumor biopsies from eight individuals (four T1N0M0 and
four T3N0M0) and normal oral tissue samples from four individuals
by immunohistochemistry. As shown in Table 1, six of eight HNSCC
tumors showed deceased levels of RPTP-β, one had normal, and one
had elevated expression compared to normal oral tissue. Among the six
with reduced RPTP-β, four also had elevated Met levels, and the other
two had normalMet levels (representative images are shown in Figure 7,
A and B). These data demonstrate that imbalance of the Met/RPTP-β
axis occurs in HNSCC tumors.
Discussion
Our data indicate that down-regulation of RPTP-β results in over-
activation of Met pathways and consequent HNSCC invasion/
metastasis. This concept is supported by our finding that RPTP-β
expression levels are substantially reduced in cell lines derived from
metastasized secondary tumors compared to the primary tumors
from the same patients. Consistent with this observation, the major-
ity of invasive HNSCC tumor samples show either reduced levels of
RPTP-β protein, increased levels of Met protein, or both.
Met is often constitutively activated in cancers, including HNSCC
tumors [1,43]. This abnormal activation can be achieved by mutations
of Met and/or overexpression of Met or HGF proteins. Our finding
that RPTP-β negatively regulates Met provides a novel mechanism of
Met activation, i.e., down-regulation of RPTP-β. In the basal state,
tyrosine phosphorylation of Met by its intrinsic PTK activity is kept
in check by RPTP-β protein tyrosine phosphatase activity. On HGF
binding, transient activation of intrinsic tyrosine kinase results in in-
creased Met tyrosine phosphorylation. In the absence of HGF, inhibi-
tion of RPTP-β activity similarly shifts the balance toward net
accumulation of tyrosine phosphorylation of Met and consequent
activation of downstream effectors [33].
Normal epithelial cells express Met but not HGF [44]. HGF is
secreted by stromal cells to activate Met in a paracrine fashion. Com-
pletion of an autocrine loop by expressing HGF in epithelial cells
or by overexpressing Met (i.e., overcoming the ability of RPTP-β to
Figure 5. RPTP-β inhibits proliferation of metastatic tumor–derived
HNSCC cells. UMSCC-22B cells were infected with empty adeno-
virus or RPTP-β adenovirus. Cells were harvested at the indicated
times post-infection and counted with a hemocytometer. Results
are means ± SEM. N = 6; *P < .05.
Figure 6. RPTP-β regulates HGF-induced HNSCC cell invasion.
(A) UMSCC-22B cells were infectedwith empty or RPTP-β–expressing
adenovirus. (B) UMSCC-22A cells were infected with NT or RPTP-β–
targeting shRNA lentivirus. Forty-eight hours post-infection, cells
(1.5× 105 cells/well) were harvested and seeded inmatrigel invasion
assay wells in Dulbecco’s modified Eagle’s medium (with 2% FBS),
with or without HGF (10 ng/ml) for 48 hours. Cells that passed through
the matrigel were stained and photographed. Representative im-
ages from three independent experiments are shown. Cells stained
purple. Matrigel stained yellow/orange.
Table 1. Staining Intensity of Met and RPTP-β Protein in HNSCC Tumor Samples.
Core No. Type Stage TNM Met Staining RPTP-β Staining
1 Malignant 3 T3N0M0 +++ −
2 Malignant 3 T3N0M0 +++ −
3 Malignant 3 T3N0M0 ++ −
4 Malignant 3 T3N0M0 ++ −
5 Malignant 1 T1N0M0 + −
6 Malignant 1 T1N0M0 ++ +
7 Malignant 1 T1N0M0 + −
8 Malignant 1 T1N0M0 ++ ++
9 Normal Normal tissue Normal tissue + +
10 Normal Normal tissue Normal tissue + +
11 Normal Normal tissue Normal tissue + +
12 Normal Normal tissue Normal tissue + +
+, Normal oral tissue level; ++ and +++, increased levels; −, reduced level.
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constrain Met activity) leads to transformation [24]. Our finding that
RPTP-β is a negative regulator of Met identifies a novel mechanism
for autocrine activation of Met, i.e., down-regulation of RPTP-β.
A deficiency of RPTP-β relative to Met (i.e., insufficient RPTP-β to
limit Met activity) would allow Met activation independent of stro-
mal cell–produced HGF. Lower RPTP-β in tumor cells can result in
higher Met activity and consequently higher metastatic potential.
Identifying RPTP-β as a new component of the HGF/Met axis shifts
the current paradigm of Met pathway regulation in cancer biology.
Given the importance of aberrant HGF/Met signaling, several dif-
ferent therapeutic strategies aimed at pathway inhibition have been
developed and are currently being evaluated in clinical trials (phases 1
and 2). Ongoing clinical trials include HGF antagonists AM102 and
c-Met inhibitors GSK1363089 (formerly XL880) and PF-02341066
(http://clinicaltrials.gov). The results from the present study could be
used to inform investigators in clinical trials of these new drugs. For
example, patients without apparent overexpression of either HGF
or Met may still have tumors that are driven by the Met pathway
because of down-regulation of RPTP-β. These patients may be good
candidates for current and future therapeutic trials targeting the
HGF/Met axis. Furthermore, on the basis of our data, RPTP-β ex-
pression may be a useful prognostic marker for HNSCC metastasis.
RPTP-β expression may identify tumors that are best suited for organ-
sparing therapy versus surgical approaches. These decisions could affect
patient quality of life and/or survival.
It is well recognized that PTK pathways are central to tumorigenesis
and the progression of many types of epithelial cancer. RPTP-β has the
potential to function as an important tumor suppressor through inhi-
bition of Met in HNSCC metastasis. Understanding regulation of the
Met pathway by RPTP-β will advance our mechanistic knowledge of
carcinogenesis and progression and could enable identification of novel
diagnostic and prognostic biomarkers.
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